FIELD: pharmaceutics.
SUBSTANCE: group of inventions relates to the field of pharmaceutics, it can be used for the treatment of brain cancer. A nucleic acid molecule encoding a chimeric antigen receptor is disclosed, wherein the given chimeric antigen receptor contains amino acid sequence SEQ ID NO: 26 or SEQ ID NO: 27. A human T-cell population, a composition for using in the treatment of brain cancer, expressing HER2, in patient, and a chimeric antigen receptor are also disclosed.
EFFECT: group of inventions provides for improved antitumor specificity.
11 cl, 18 dwg, 3 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INTRODUCTION OF CONSTRUCTED T CELLS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCER | 2017 |
|
RU2757308C2 |
| CHIMERIC ANTIGEN RECEPTORS AIMED AT PSCA | 2016 |
|
RU2759879C2 |
| T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
| CENTRAL MEMORY T-CELLS FOR ADOPTIVE T-CELL THERAPY | 2015 |
|
RU2763523C2 |
| T-CELLS MODIFIED WITH CHIMERIC ANTIGEN RECEPTOR TARGETED TO CS1 FOR TREATMENT OF AMYLOIDOSIS AL | 2018 |
|
RU2774895C2 |
| T-CELLS MODIFIED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING CS1 | 2015 |
|
RU2727451C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED TO FC RECEPTOR-LIKE PROTEIN 5, AND THEIR USE | 2015 |
|
RU2779747C2 |
| MODIFIED Α1-Α2 DOMAINS OF NON-NATURAL NKG2D LIGANDS THAT BIND TO NON-NATURAL NKG2D RECEPTORS | 2019 |
|
RU2815278C2 |
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
